European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical Cancer

Article

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

The European Commission has approved pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab (Avastin) for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 and who have a combined positive score of 1 or greater, according to a press release from Merck.1

The approval was based on findings from the phase 3 KEYNOTE-826 trial (NCT03635567), which assessed pembrolizumab plus chemotherapy plus or minus bevacizumab vs chemotherapy.2 Patients had an improved overall survival (OS; HR, 0.64; 95% CI, 0.50-0.81; P = .0001), and progression-free survival (HR, 0.62; 95% CI, 0.50-0.77; P <.0001) compared with the placebo arm.

“With today’s approval, healthcare providers in the EU will be able to offer certain patients with advanced cervical cancer a long-awaited immunotherapy option that has shown significant improvement in [OS].” Nicoletta Colombo, MD, PhD, associate professor at the University of Milan-Bicocca, and director of the Gynecologic Oncology Program at the European Institute of Oncology in Milan, Italy, said in a press release

Pembrolizumab plus chemotherapy with or without bevacizumab has previously been approved by the FDA in October 2021 and was based on the results from the phase 3 KEYNOTE-826 trial.3

References

  1. European Commission approved Merck’s Keytruda (pembrolizumab) plus chemotherapy, with or without bevacizumab, for patients with persistant, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1). News Release. Merck. April 29, 2022. Accessed May 2, 2022. https://bit.ly/3kxze1D
  2. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
  3. FDA approves Merck’s Keytruda (pembrolizumab) plus chemotherapy, with or without bevacizumab, as treatment for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1). News Release. Merck. October 13, 2021. Accessed May 2, 2022. https://bit.ly/3vXoS0u
Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Survey Says Gaps Exist in Gynecologic Cancer Treatment

Tim Cortese
November 15th 2024
Article

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Induction Chemotherapy Combination Boosts PFS/OS in Cervical Cancer

Tim Cortese
November 3rd 2024
Article

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.